ArticleGynecologic oncology reports2025
Uterine endometrioid adenocarcinoma with pilomatrix-like differentiation: A case report and review of the literature.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- ER-Negative Endometrial Cancers: An Evolving Diagnostic Category with Major Clinical Implications.Cancers · 2026Review
- Differential Localization of β-Catenin Protein in CTNNB1 Mutant Endometrial Cancers Results in Distinct Transcriptional Profiles.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: We present a rare case of uterine pilomatrix-like high grade endometrioid carcinoma (PiMHEC). We provide a thorough review of the 16 other PiMHEC cases reported to date, overview of our index case, and considerations for therapeutic approach with a focus on molecular subtyping. Case Summary: This 44-year-old patient presented with widespread metastatic disease at time of diagnosis and initial clinical improvement with combination chemoradiotherapy. Immunotherapy was initiated later in the clinical course and the patient ultimately died of their disease 6 months post-diagnosis. Conclusion: Future clinicians may utilize PiMHEC case reports to formulate a therapeutic regimen and consider early initiation of immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.